The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Intravenous (IV) Ibuprofen Market During 2026–2030?

The market size for intravenous (iv) ibuprofen has expanded significantly in recent years. It is anticipated to increase from $9.37 billion in 2025 to $10.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.1%. This historical growth can be attributed to several factors such as the rising need for postoperative pain management, the prevalent use of NSAIDs in hospital settings, an increase in surgical procedure volumes, the growing occurrence of acute inflammatory conditions, and the established clinical effectiveness of ibuprofen for both pain and fever relief.

The intravenous (iv) ibuprofen market is projected to experience substantial growth over the coming years, reaching $16.41 billion by 2030, with a compound annual growth rate (CAGR) of 11.8%. This expansion during the forecast period is driven by factors such as the increasing need for pain management strategies that reduce opioid use, the wider acceptance of IV therapies in outpatient surgical centers, an increase in hospitalizations among children and the elderly, the development of acute care facilities, and a rising demand for quickly effective pain relief. Key developments anticipated in this period encompass the increased use of iv ibuprofen for managing post-surgery pain, a growing reliance on non-opioid pain relievers in acute care, a preference for injectable pain treatments that work fast, the broader application of iv ibuprofen in pediatric and critical care environments, and the introduction of more concentrated iv ibuprofen formulations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23429&type=smp

Which Major Factors Are Contributing To The Development Of The Intravenous (IV) Ibuprofen Market?

The increasing occurrence of pain conditions is projected to drive the expansion of the intravenous ibuprofen market in the future. These disorders are defined as health issues marked by ongoing or long-term pain that interferes with daily activities, frequently stemming from problems with nerves, muscles and bones, or inflammation. The growing incidence of pain disorders is attributed to an aging demographic, given that elderly individuals are more susceptible to developing chronic ailments such as arthritis, osteoarthritis, and nerve-related pain, thereby boosting the demand for efficient pain management. Intravenous ibuprofen aids in pain control by delivering rapid alleviation, rendering it particularly suitable for acute and post-surgical discomfort. It diminishes inflammation and improves patient well-being, thus increasing the efficacy of treatment within healthcare environments. For example, data from January 2024, provided by the Office for Health Improvement and Disparities, a UK-based government department, indicated that the proportion of people aged 16 and older reporting a long-term musculoskeletal condition climbed to 18.4% in 2023, an increase from 17.6% in 2022. Consequently, the increased occurrence of pain disorders is propelling the expansion of the intravenous ibuprofen market.

How Does Segment Analysis Break Down The Intravenous (IV) Ibuprofen Market Structure?

The intravenous (iv) ibuprofen market covered in this report is segmented –

1) By Product Type: Conventional Intravenous (IV) Ibuprofen, High-Concentration Intravenous (IV) Ibuprofen

2) By Strength: 100 Milligrams (mg), 200 Milligrams (mg), 400 Milligrams (mg), 800 Milligrams (mg)

3) By Age Group: Pediatrics, Adults

4) By Application: Pain, Fever, Inflammation, Other Applications

5) By End-User: Hospitals, Ambulatory Surgical Centers, Clinics, Other End-Users

Subsegments:

1) By Conventional Intravenous (IV) Ibuprofen: Pediatric Intravenous (IV) Ibuprofen, Adult Intravenous (IV) Ibuprofen

2) By High-Concentration Intravenous (IV) Ibuprofen: Single-Dose Vial, Multi-Dose Vial

What Trends Are Driving Changes In The Intravenous (IV) Ibuprofen Market?

Major companies in the intravenous ibuprofen market are prioritizing the creation of advanced drug formulations, such as opioid-free analgesics, to enhance pain management while reducing opioid dependence. An opioid-free analgesic is a pain-relieving medicine that does not contain opioids, thereby avoiding the risk of addiction and opioid-related side effects. For instance, in February 2024, Hikma Pharmaceuticals plc, a pharmaceutical company based in the UK, launched COMBOGESIC IV (acetaminophen and ibuprofen) injection in the US, following its Food and Drug Administration (FDA) approval in October 2023. This intravenous, opioid-free analgesic is prescribed for mild to moderate pain relief and as a complementary treatment for moderate to severe pain management. By bringing together two active ingredients with unique mechanisms, COMBOGESIC IV presents healthcare providers with an innovative, non-opioid option for pain management.

Who Are The Major Companies Operating In The Intravenous (IV) Ibuprofen Market?

Major companies operating in the intravenous (iv) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Dr. Reddy’s Laboratories, Hikma Pharmaceuticals plc, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, Hyloris Pharmaceuticals SA

Access The Complete Intravenous (IV) Ibuprofen Market Report:

https://www.thebusinessresearchcompany.com/report/intravenous-iv-ibuprofen-global-market-report

Which Region Contributes The Most To The Intravenous (IV) Ibuprofen Market?

North America was the largest region in the intravenous (IV) ibuprofen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous (iv) ibuprofen market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Intravenous (IV) Ibuprofen Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=23429&type=smp

Browse Through More Reports Similar to the Global Intravenous (IV) Ibuprofen Market 2026, By The Business Research Company

Cardiovascular Ultrasound Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-ultrasound-global-market-report

Vascular Imaging Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Contrast Enhanced Ultrasound Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/contrast-enhanced-ultrasound-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.